This is the authors' abstract. We don't add key points for this paper.
Fibroblast growth factor 19 (FGF19) belongs to a diverse family of growth factors with pivotal roles spanning from cell differentiation to angiogenesis and tissue repair. Within the expansive FGF family, FGF19 forms a distinctive subfamily, including FGF19, FGF21 and FGF23. Members of this subfamily exhibit limited affinity for heparin/heparan sulfate (HS), allowing them to function endocranially and maintain cellular homeostasis. FGF19, in particular, is known for its role in downregulating bile acid synthesis. However, its pharmaceutical significance mainly lies in its capacity to regulate glucose levels and enhance energy expenditure in adipocytes. This study presents a preliminary assessment of FGF19's affinity for HS, conducted through two purification processes involving nickel and heparin columns. The initial findings reveal a significant binding interaction between FGF19 and HS although less than canonical HS binding FGFs such as FGF1 and FGF2. Additionally, FGF19 was found to be very prone to trypsin digestion, suggesting a highly dynamic and flexible molecule. Lastly, differential scanning calorimetry (DSC) investigations indicated a thermal stability profile with a Tm of 44 °C. Collectively, these findings provide crucial insights into FGF19's stability and raise intriguing questions regarding the role of HS in its signaling mechanism. The comprehensive understanding of FGF19's mode of action and stability is paramount for its potential applications in addressing lipid and glucose disorders, such as non-alcoholic steatohepatitis (NASH) and diabetes-induced obesity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ternier et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: